Jubilant Life Sciences rose 7.26% to Rs 335.25 at 10:10 IST on BSE after consolidated net profit surged 2579.08% to Rs 128.06 crore on 1.52% decline in net sales to Rs 1438.38 crore in Q1 June 2015 over Q1 June 2014.
The result was announced at the fag end of the trading session yesterday, 11 August 2015. Shares of Jubilant Life Sciences surged 10.64% to Rs 312.55 on that day. The stock has risen 18.67% in two sessions from Rs 282.50 on Monday, 10 August 2015.
Meanwhile, the BSE Sensex was down 163.50 points, or 0.59%, to 27,702.59.
On BSE, so far 7.93 lakh shares were traded in the counter, compared with an average volume of 2.13 lakh shares in the past one quarter.
The stock hit a high of Rs 354.70 so far during the day, which is also 52-week high for the counter. The stock hit a low of Rs 328.65 so far during the day. The stock hit a 52-week low of Rs 116.10 on 17 December 2014.
The stock had outperformed the market over the past one month till 11 August 2015, rising 54.69% compared with 0.74% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 86.99% as against Sensex's 1.30% rise.
The mid-cap company has an equity capital of Rs 15.93 crore. Face value per share is Re 1.
Jubilant Life Sciences' consolidated EBITDA (earnings before interest, taxes, depreciation and amortization) (including other income) rose 123% to Rs 333 crore in Q1 June 2015 over Q1 June 2014. EBITDA margins were reported at 22.8% in Q1 June 2015, higher than 10.2% in Q1 June 2014.
Previous periods figures have been reclassified to conform to the current period's classification. Further, the figures for the current period are not comparable to the previous periods due to transfer of certain businesses to Jubilant Generics, a step-down wholly owned subsidiary with effect from 1 July 2014.
In Q1 June 2015, income from operations of the pharmaceuticals segment was at Rs 741 crore, contributing 51% to the revenue mix. The segment EBITDA stood at Rs 225 crore, with EBITDA margins at 30.4% in Q1 June 2015.
In Q1 June 2015, income from operations of the life science ingredients segment stood at Rs 718 crore, contributing 49% to the revenue mix. The segment EBITDA stood at Rs 121 crore, with EBITDA margins at 16.9%.
In Q1 June 2015, revenues from North America stood at Rs 619 crore, contributing 42% to the overall revenues. Revenues from Europe and Japan stood at Rs 254 crore, contributing 17% to the revenue mix. Domestic revenues stood at Rs 402 crore, thus contributing 28% to the overall mix. Revenues in ROW (Rest of World) including China was at Rs 184 crore, thus contributing 13% to the overall mix.
In its outlook, the company said that in the year ending March 2016 (FY 2016), the revenue growth is expected to be driven by pharmaceuticals segment primarily led by growth in radiopharmaceuticals, normalization of CMO (contract manufacturing organisation) business and growth in generics business through new products. The company's Life Science Ingredients segment is expected to deliver better results compared to In the year ending March 2015, led by improved operational efficiency and growth in Nutritional Products and Specialty Ingredients.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and life science ingredients. It also provides services in contract manufacturing of sterile injectables and drug discovery solutions. The company's strength lies in its unique offerings of pharmaceuticals and life sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of around 6000 multicultural people across the globe, the company is committed to deliver value to its customers spread across over 100 countries.
Powered by Capital Market - Live News
